RxDoctor Payments DataLook up a doctor →

Patricia Morgan, MD

Neurology · Hammond, LANPI 1174783070

Payments from drug & device makers

$16,254in general payments, 2019–2025

Across 920 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • SK Life Science, Inc.$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lundbeck LLC$1K
  • Amgen$859
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)119$1,798
UCB, Inc.76$1,446
SK Life Science, Inc.60$1,160
Teva Pharmaceuticals USA, Inc.76$1,143
Lundbeck LLC54$1,101
Amgen(2 entities)51$859
Pfizer50$855
Supernus Pharmaceuticals, Inc.55$693
Jazz Pharmaceuticals Inc.32$646
Lilly USA, LLC29$569
Novartis28$487
Kyowa Kirin, Inc.17$346
Eisai Inc.12$296
Argenx US, Inc.14$286
Biogen14$274
Collegium Pharmaceutical, Inc.13$245
MDD US Operations, LLC12$236
AstraZeneca8$192
Biohaven Pharmaceuticals, Inc.12$191
Otsuka America Pharmaceutical, Inc.9$190
Biohaven Pharmaceutical Holding Company Ltd.13$188
Johnson & Johnson(2 entities)9$182
Greenwich Biosciences, Inc.6$175
GE HealthCare7$173
Takeda Pharmaceuticals U.S.A., Inc.7$171
CSL Behring7$166
Bristol Myers Squibb9$143
Neurelis, Inc.5$135
Zyla Life Sciences, Inc.21$135
Sanofi7$128
Nevro Corp.5$114
Axsome Therapeutics, Inc.6$110
Neurocrine Biosciences, Inc.6$105
Upsher-smith Laboratories LLC6$98
Impel Pharmaceuticals Inc.5$97
Arbor Pharmaceuticals, Inc.5$86
Scilex Pharmaceuticals Inc.4$76
Tersera Therapeutics LLC3$61
Grifols USA, LLC3$59
Merz Pharmaceuticals, LLC2$54
Currax Pharmaceuticals LLC3$46
Abbott2$43
GRT US Holding, Inc.2$42
Virtus Pharmaceuticals LLC2$39
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$39
Medtronic(2 entities)2$38
Forte Bio-pharma LLC2$38
Globus Medical2$36
Alfasigma USA, Inc.2$35
Almatica Pharma LLC2$30
Sanofi-aventis U.S. LLC2$28
Acorda Therapeutics, Inc1$25
E.r. Squibb & Sons, L.L.C.1$25
Otsuka Pharmaceutical Development & Commercialization, Inc.1$25
Pacira Pharmaceuticals Incorporated1$23
Ultragenyx Pharmaceutical Inc.1$23
Averitas Pharma Inc.1$22
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$22
Boston Scientific1$21
Convatec Inc.1$20

How this compares

$16,254 in reported general payments places this provider in the 75th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana →

Medicare billing

Part B allowed, 2024
$151,179
Medicare patients
392
Services billed
918

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Hammond

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →